[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Iyoda A, Hiroshima K, Moriya Y, Sekine Y, Shibuya K, Iizasa T, Nakatani Y, Fujisawa T: Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma. J Thorac Cardiovasc Surg; 2006 Aug;132(2):312-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma.
  • BACKGROUND: Most patients with pathologic stage Ia non-small cell lung carcinoma have a good prognosis, and adjuvant chemotherapy is currently not being used in the management of this stage of the disease.
  • However, if significant negative prognostic factors become evident in patients with pathologic stage Ia non-small cell lung carcinoma, patients with negative prognostic factors should have adjuvant treatment after surgery.
  • METHODS: We analyzed 335 cases of pathologic stage Ia non-small cell lung carcinoma treated between 1988 and 2003 by complete resection.
  • The pathologic stage Ia non-small cell lung carcinomas comprised 259 adenocarcinomas, 65 squamous cell carcinomas, and 11 large cell neuroendocrine carcinomas.
  • CONCLUSIONS: Large cell neuroendocrine histology has a significant adverse prognostic impact on pathologic stage Ia non-small cell carcinoma.
  • Therefore, surgical resection alone represents insufficient treatment for large cell neuroendocrine carcinoma, even for pathologic stage Ia disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Carcinoma, Neuroendocrine / mortality. Carcinoma, Neuroendocrine / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872955.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, Uno K: Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer; 2006 Nov 15;107(10):2468-73
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma.
  • BACKGROUND: [(18)F]Fluoro-2-deoxyglucose uptake on positron emission tomography (FDG-PET) has been frequently used for diagnosis and staging of lung cancer.
  • The prognostic significance of FDG uptake on PET was evaluated in patients with pathologic Stage I lung adenocarcinoma (tumor stages were based on the TNM classification of the International Union Against Cancer).
  • METHODS: Disease-free survival of 98 patients with pathologic Stage I lung adenocarcinoma who were treated by curative resection was examined in relation to sex, age, histologic grade of differentiation, surgical procedure, tumor stage, and FDG uptake measured as the maximum standardized uptake value (SUV).
  • RESULTS: Sixty-three patients were had Stage IA disease and 35 patients had Stage IB disease.
  • Six patients each with Stage IA and Stage IB disease developed disease recurrence after a mean postsurgical follow-up period of 31 months.
  • Ten (23%) of the 43 patients with SUV > or = 3.3 developed a recurrence compared with 2 (4%) of the 55 patients with SUV < 3.3 (P = .020).
  • Ten (20%) of the 51 patients with moderately or poorly differentiated adenocarcinoma developed disease recurrence, compared with 2 (4%) of the 47 patients with well-differentiated adenocarcinoma (P = .056).
  • CONCLUSIONS: FDG uptake appears to be predictive of disease-free survival in patients with Stage I lung adenocarcinoma.
  • FDG uptake could yield important information for determining the likely value of postoperative adjuvant chemotherapy in such patients.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036361.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


3. Ost D, Goldberg J, Rolnitzky L, Rom WN: Survival after surgery in stage IA and IB non-small cell lung cancer. Am J Respir Crit Care Med; 2008 Mar 1;177(5):516-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after surgery in stage IA and IB non-small cell lung cancer.
  • RATIONALE: Whether histologic subtype of non-small cell lung cancer (NSCLC) has an important effect on prognosis after surgery is unknown.
  • (1) primary squamous cell or adenocarcinoma;.
  • (3) lymph node dissection performed; and (4) pathologic stage IA or IB.
  • For both all-cause and lung cancer-associated mortality, tumor size demonstrated the strongest association (log-rank P < 0.0001 for each).
  • When tumors were small (</=2 cm), lung cancer-associated mortality was similar for adenocarcinoma when compared with squamous cell carcinoma.
  • When tumors were 3 cm or larger in size, lung cancer-associated mortality was higher for adenocarcinoma.
  • The increased risk of lung cancer-associated mortality with adenocarcinoma was more pronounced in those younger than 65 years.
  • CONCLUSIONS: Staging that takes into account size, histology, late recurrence risk, and patient age is more accurate than the current TNM system and is clinically relevant because improved prediction can facilitate better decisions on the use of adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / mortality. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Prognosis. Proportional Hazards Models. Risk Assessment. SEER Program

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Oct 26;343(17):1217-22 [11071672.001]
  • [Cites] Clin Chem. 2002 Nov;48(11):1931-7 [12406978.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61 [14519751.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):404-5 [14736933.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Jul;26(1):173-82 [15200998.001]
  • [Cites] Thorax. 2004 Aug;59(8):679-81 [15282388.001]
  • [Cites] J Surg Oncol. 1987 Jul;35(3):147-56 [3037195.001]
  • [Cites] Lung Cancer. 1996 Mar;14 Suppl 1:S99-105 [8785673.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2640-2 [15972872.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4999-5006 [16051951.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4049-54 [16618724.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):249-55 [17534168.001]
  • [CommentIn] Am J Respir Crit Care Med. 2008 Nov 15;178(10):1090; author reply 1090 [18987348.001]
  • (PMID = 18006887.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2 P30 CA 16087
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2258444
  •  go-up   go-down


Advertisement
4. Hamada C, Tsuboi M, Ohta M, Fujimura S, Kodama K, Imaizumi M, Wada H: Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. J Thorac Oncol; 2009 Dec;4(12):1511-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials.
  • BACKGROUND: The Seventh Edition of the Tumor, Node, Metastasis Classification of Malignant Tumors in non-small cell lung cancer (NSCLC) proposes a more detailed classification of primary tumor diameter.
  • Stage IA T1 disease is subdivided into two groups: T1a disease (tumor diameter, < or = 2 cm) and T1b disease (tumor diameter, >2 to < or = 3 cm).
  • Tegafur-uracil (UFT) improves survival in patients with stage I NSCLC.
  • However, whether it is effective in patients with T1 disease (stage IA) remains controversial.
  • In the surgery-alone group, survival rates at 5 years were 85% in patients with T1a tumors and 82% in those with T1b tumors after surgery alone and 87% in patients with T1a tumors and 88% in those with T1b tumors after surgery followed by adjuvant treatment with UFT.
  • The results of a test for interaction between treatment response and T1 subgroup were not significant (p = 0.30).
  • CONCLUSIONS: UFT significantly improves survival in patients with stage IA T1b NSCLC compared with surgery alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Aged. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Chemotherapy, Adjuvant. Female. Humans. Male. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Survival Rate. Tegafur / therapeutic use. Treatment Outcome. Uracil / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875974.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


5. Bekki J, Katayama S, Orihashi N, Nakagi H, Yamada A: [A case of recurrent lung cancer successfully treated using ambulatory chemotherapy with vinorelbine]. Gan To Kagaku Ryoho; 2002 Mar;29(3):431-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent lung cancer successfully treated using ambulatory chemotherapy with vinorelbine].
  • She had previously suffered from stage IA lung adenocarcinoma and undergone a right upper lobe resection.
  • Combination chemotherapy with cisplatin (CDDP) and docetaxel (TXT) failed to produce an antitumor effect.
  • The treatment was changed to ambulatory chemotherapy with vinorelbine (VNB) at 20 mg/m2 weekly.
  • As VNB is easy to administer, it will be applicable in ambulatory chemotherapy administered with consideration of the patients quality of life.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ambulatory Care. Antineoplastic Agents, Phytogenic / administration & dosage. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915734.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


6. Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, Kiefe CI, Weeks JC, West DW, Zafar SY, Fletcher RH: Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol; 2010 Feb 1;28(4):620-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.
  • PURPOSE: To describe chemotherapy use and adverse events (AEs) for advanced-stage, non-small-cell lung cancer (NSCLC) in community practice, including descriptions according to variation by age.
  • AEs were medical events occurring during chemotherapy.
  • Using logistic regression, we assessed the association between age and chemotherapy; with Poisson regression, we estimated event rate ratios and adjusted the analysis for age, sex, ethnicity, radiation therapy, stage, histology, and presence and grade of 27 comorbidities.
  • RESULTS: Of 1,371 patients, 58% (95% CI, 55% to 61%) received chemotherapy and 35% (95% CI, 32% to 38%) had AEs.
  • After adjustment, 72% (95% CI, 65% to 79%) of those younger than 55 years and 47% (95% CI, 42% to 52%) of those age 75 years and older received chemotherapy.
  • Platinum-based therapies were less common in the older-age groups.
  • In contrast, older adults were more likely to have AEs during chemotherapy.
  • CONCLUSION: Older patients who received chemotherapy had fewer pretherapy events than younger patients and were less likely to receive platinum-based regimens.
  • Nevertheless, older patients had more adverse events during chemotherapy, independent of comorbidity.
  • Potential implicit trade-offs between symptom management and treatment toxicity should be made explicit and additionally studied.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] Chest. 2000 May;117(5):1239-46 [10807806.001]
  • [Cites] Health Qual Life Outcomes. 2008;6:84 [18939982.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1064-70 [11181670.001]
  • [Cites] Oncologist. 2001;6 Suppl 1:4-7 [11181997.001]
  • [Cites] Biometrics. 1999 Jun;55(2):652-9 [11318229.001]
  • [Cites] Lung Cancer. 2001 Sep;33 Suppl 1:S115-20 [11576716.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):779-88 [12910523.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2992-6 [15284250.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3261-8 [15310770.001]
  • [Cites] Lung Cancer. 2004 Oct;46(1):61-76 [15364134.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Lung Cancer. 1995 Dec;13(3):235-52 [8719064.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):392-7 [9155522.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1582-7 [9552069.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1930-7 [9806651.001]
  • [Cites] Lung Cancer. 1998 Aug;21(2):105-13 [9829544.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4971-8 [15611512.001]
  • [Cites] Chest. 2005 Aug;128(2):947-57 [16100191.001]
  • [Cites] Intern Med J. 2006 Apr;36(4):216-20 [16640737.001]
  • [Cites] Support Care Cancer. 2006 Aug;14(8):837-48 [16482448.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5570-7 [18065729.001]
  • [CommentIn] J Clin Oncol. 2010 Feb 1;28(4):523-6 [20038720.001]
  • [ErratumIn] J Clin Oncol. 2010 May 1;28(13):2314
  • (PMID = 20038726.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / AHRQ HHS / HS / 5 U18 HS016094; United States / PHS HHS / / U01 A093326; United States / NCI NIH HHS / CA / U01 CA093329; United States / NCI NIH HHS / CA / U01 CA093348; United States / NCI NIH HHS / CA / U01 CA093324; United States / AHRQ HHS / HS / U18 HS016094; United States / NCI NIH HHS / CA / U01 CA093344; United States / NCI NIH HHS / CA / U01 CA093332; United States / NCI NIH HHS / CA / U01 CA01013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2815997
  •  go-up   go-down


7. Ou SH, Zell JA, Ziogas A, Anton-Culver H: Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer; 2007 Oct 1;110(7):1532-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003.
  • BACKGROUND: Platinum-based adjuvant chemotherapy in randomized trials has failed to provide a survival benefit in patients with resected stage I nonsmall cell lung cancer (NSCLC).
  • Using data from the California Cancer Registry (CCR), we explored factors that had detrimental effects on survival in patients with stage I NSCLC to identify a subset of patients at high risk for disease recurrence and subsequent mortality.
  • METHODS: Between 1989 and 2003, 19,702 incident cases of stage I NSCLC in the CCR were identified and subgrouped into stage IA and IB disease.
  • Patient demographic factors, tumor characteristics, and treatment delivered were examined.
  • RESULTS: Advanced age at diagnosis, male sex, low socioeconomic status (SES), nonsurgical treatment, and poor histologic grade (stage IA NSCLC: hazards ratio [HR], 1.13; 95% confidence interval [95% CI], 1.08-1.19; stage IB NSCLC: HR, 1.11; 95% CI, 1.07-1.16) were associated with increased mortality risk on multivariate analysis.
  • Non-upper lobe tumor location (right middle lobe, right and left lower lobes) and tumor size > or =4 cm (vs <4 cm: HR, 1.23; 95% CI, 1.15-1.30) were additional factors that increased the risk of mortality among patients with stage IB disease.
  • Bronchioloalveolar carcinoma and Asian ethnicity were associated with decreased mortality risk in stage I NSCLC.
  • CONCLUSIONS: Stage I NSCLC with poorly differentiated histology and stage IB NSCLC with non-upper lobar tumor location or tumor size > or =4 cm carried an increased mortality risk.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / mortality. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Asian Americans / statistics & numerical data. California / epidemiology. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pneumonectomy / methods. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Registries. Risk Assessment. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702091.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Kashiwabara K, Saeki S, Sasaki J, Nomura M, Kohrogi H: Combined evaluation of postoperative serum levels of carcinoembryonic antigen less than or equal to 2.5 ng/ml and absence of vascular invasion may predict no recurrence of stage I adenocarcinoma lung cancer. J Thorac Oncol; 2008 Dec;3(12):1416-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined evaluation of postoperative serum levels of carcinoembryonic antigen less than or equal to 2.5 ng/ml and absence of vascular invasion may predict no recurrence of stage I adenocarcinoma lung cancer.
  • STUDY OBJECTIVES: It has been reported that high levels of serum carcinoembryonic antigen (CEA) after surgery, or the presence of vascular invasion or both, are strong indicators of postoperative recurrence in patients with non-small cell lung cancer.
  • The purpose of this study is to evaluate which kind of patients with p-stage I adenocarcinoma need adjuvant chemotherapy, using those predictors.
  • PATIENTS AND METHODS: We studied 136 patients with curatively resected p-stage I adenocarcinoma during the 7-year period of January 1, 2000 to December 31, 2006.
  • RESULTS: The median time of follow-up after surgery was 28.3 months.
  • Fifteen (11%) of 136 patients had postoperative recurrence (7 p-stage IA cases and 8 p-stage IB cases).
  • CONCLUSION: Combined evaluation of postoperative CEA levels and vascular invasion makes it possible to predict disease recurrence in the curatively resected p-stage I adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / blood. Carcinoembryonic Antigen / blood. Lung Neoplasms / blood. Neoplasm Recurrence, Local / diagnosis. Neovascularization, Pathologic / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Postoperative Period. Prognosis. ROC Curve. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057266.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


9. Ohta S, Hirose M, Ishibashi H, Muro H: [Is adjuvant chemotherapy necessary for the peripherally located stage I adenocarcinoma of the lung?]. Kyobu Geka; 2007 Jul;60(7):519-22; discussion 522-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is adjuvant chemotherapy necessary for the peripherally located stage I adenocarcinoma of the lung?].
  • OBJECTIVE: This study was done for the purpose of picking out the cases of poor prognosis from the peripherally located stage I adenocarcinoma of the lung.
  • METHODS: Between January 1989 and December 2004, 235 patients with peripherally located stage I adenocarcinoma of the lung were resected curatively in our hospital.
  • The ratio of the cases without ductal invasion was 61% in stage IA, and 31% in stage IB.
  • The 5-year survival rate was 99% in the cases without ductal invasion in stage IA, 100% in the cases without ductal invasion in stage IB, 90% in the cases with ductal invasion in stage IA, and 65% in the cases with ductal invasion in stage IB, respectively.
  • And the 5-year survival rate without recurrence was 94% in the cases without ductal invasion in stage IA, 76% in the cases without ductal invasion in stage IB, 76% in the cases with ductal invasion in stage IA, and 54% in the cases with ductal invasion in stage IB, respectively.
  • CONCLUSIONS: Ductal invasion is significant prognostic factor in stage I adenocarcinoma of the lung.
  • Adjuvant chemotherapy is unnecessary for the case without ductal invasion in stage IA.
  • But we think that adjuvant chemotherapy is necessary for the case with ductal invasion in stage IA and for the case in stage IB, because there is much recurrence.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Pneumonectomy
  • [MeSH-minor] Blood Vessels / pathology. Chemotherapy, Adjuvant. Humans. Lymphatic Vessels / pathology. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642210.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, Orikasa H, Yamazaki K, Uno K, Kobayashi T, Goya T: [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol; 2006 Jul;36(7):403-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas.
  • OBJECTIVE: To predict a malignant grade of lung cancer by fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, we investigated the correlation between FDG uptake and pathological tumor stage, proliferative activities determined by Ki-67 and cyclin D1, and an alteration of p53, in clinical stage (c-stage) IA lung adenocarcinomas.
  • METHODS: FDG-PET was performed for 71 patients with c-stage IA lung adenocarcinomas.
  • FDG uptake was measured by a contrast ratio (CR) between the tumor and contralateral lung.
  • RESULTS: The lesions with ground-glass opacity were found in 26 patients, and solid lesions in 45 by computed tomography.
  • The pathological tumor stages (p-stage) were stage IA in 59 and more advanced stages in 12.
  • The CR and staining scores of Ki-67 were significantly correlated with each other (P < 0.0001), and both the values were significantly higher in advanced tumor stages than in p-stage IA, and were also significantly higher in tumors with intratumoral lymphatic, vascular and pleural involvements than in those without such features (P < 0.05-0.0001).
  • CONCLUSIONS: In c-stage IA lung adenocarcinomas, the FDG uptake can predict p-stage and tumor proliferative activity determined by Ki-67.
  • For c-stage IA lung adenocarcinomas showing CR > or = 0.55, mediastinoscopy or neoadjuvant chemotherapy is indicated.
  • [MeSH-major] Adenocarcinoma / pathology. Fluorodeoxyglucose F18. Lung Neoplasms / pathology. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782729.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0 / Tumor Suppressor Protein p53; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 136601-57-5 / Cyclin D1
  •  go-up   go-down


11. Ayabe T, Matsuzaki Y, Shimizu T, Hara M, Tomita M, Onitsuka T: [pN0 stage IA lung cancer downstaged from pN2 IIIA by induction therapy; report of a case]. Kyobu Geka; 2006 Sep;59(10):955-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [pN0 stage IA lung cancer downstaged from pN2 IIIA by induction therapy; report of a case].
  • A 75-year-old male of adenocarcinoma in non-small cell lung cancer (NSCLC) was diagnosed to be p-staged IIIA by a preoperative mediastinoscopy.
  • After the induction chemotherapy of cisplatin (80 mg/m2, day 1, 4 weeks, 2 cycles) plus docetaxel hydrate (60 mg/m2, day 1, 4 weeks, 2 cycles), we performed lobectomy and lymph nodes dissection.
  • The postoperative stage has been down to be pN0 IA from pN2 IIIA.
  • After the adjuvant therapy of docetaxel hydrate (60 mg/m2, day 1, 4 weeks, 2 cycles), the postoperative serum carcinoembryonic antigen level has been normalized without a recurrence for more than 2 years.
  • A pathological staging with a mediastinoscopic diagnosis for the suspected clinical IIIA-staged NSCLC should bring us a good assessment of the induction therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / surgery. Lymph Node Excision. Mediastinoscopy. Pneumonectomy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Neoplasm Staging. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986695.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Mizuno T, Ishii G, Nagai K, Yoshida J, Nishimura M, Mochizuki T, Kawai O, Hasebe T, Ochiai A: Identification of a low risk subgroup of stage IB lung adenocarcinoma patients. Lung Cancer; 2008 Dec;62(3):302-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a low risk subgroup of stage IB lung adenocarcinoma patients.
  • OBJECTIVES: Several trials have recently reported the efficacy of adjuvant chemotherapy for resected stage IB non-small cell lung cancer (NSCLC).
  • However, the histological findings and prognosis of stage IB lung adenocarcinoma vary considerably.
  • The aim of this study was to investigate prognostic factors of resected stage IB adenocarcinoma and identify a subgroup with a better prognosis, in which adjuvant chemotherapy could be omitted.
  • METHODS: We reviewed 413 cases of stage I lung adenocarcinoma treated by surgical resection, and investigated prognostic factors that favorably affected the survival of 106 patients with stage IB lung adenocarcinoma.
  • A subgroup with a better outcome was identified and their survival was compared with that of stage IA patients.
  • RESULTS: The 5-year survival rate of the stage IB adenocarcinoma patients was 81.7%.
  • The 5-year survival rate of the stage IB adenocarcinoma patients without pleural invasion (76 cases) was 89.3%, and it was not statistically different from that of the stage IA patients (92.7%).
  • CONCLUSIONS: The stage IB lung adenocarcinoma patients without pleural invasion had a favorable outcome that was almost the same as that of stage IA patients.
  • Because adverse effects of chemotherapy are sometimes severe and unacceptable, adjuvant chemotherapy can be omitted for stage IB adenocarcinoma without pleural invasion.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486987.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


13. Rubio-Martínez A, Recasens V, Martos C, Montañés A, García-Carpintero G, Gómez-López L, Rubio-Félix D, Giraldo P: Predictive factors to develop a second neoplasia in a Hodgkin disease cohort patients. J Clin Oncol; 2004 Jul 15;22(14_suppl):6707

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The importance of late effects of therapy have become more apparent.
  • VARIABLES: demographic data, date of HL diagnosis, histological subtype, stage, treatment schedule (chemotherapy, radiotherapy, combined), date SM diagnosis, subtype and location of cancer.
  • Cohort was stratified according to age, gender and schedule of therapy.
  • Subtype: NE 71%, MC22%, LP 24; stage: IA 12.7%, IB 1.6%, IIA 27.9%, IIB 5%, IIIA 16.9%, IIIB 14.4% IVA 9.3% IVB 11.8%.
  • Radiotherapy 16.1% (mantle 50%, inverted-Y 11.8 %, both: 1.6%;cobalt 59.3%, linear accelerator 4.2%; total dose 20-36 Gy), chemotherapy 39.8% (ABVD 14.4%, MOPP 15.5%, CMOPP 23.7%, CMOPP/ABVD 18.6%, ABVD/MOPP 15.2%), combined 44%.
  • HL relapsed: 10.1%, mean time: 49 m.
  • Developed a SM 15(12.7%), mean 102.3 m; range 9-285: 11 a non-hematological neoplasia: adenocarcinoma (colon, breast, lung, oropharynx, skin, cavum, parotida. thyroid) and 4 a hematological neoplasia (AML and NHL).
  • CONCLUSIONS: The incidence of SM among long-time survivors of HL is higher than in normal population.
  • In other essays the major risk has been observed in patients treated with radiotherapy either alone or combined with chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014611.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sakamoto K, Koshiishi H, Kakimoto M, Nishida K, Masuda T, Chika N, Hosokawa T, Matsuyama T, Tokita H, Goto H, Yoshimura T, Okamura T, Dan N, Kato H, Mitsuhashi Y: [A case of synchronous double cancer of stomach and lung responding to neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2795-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous double cancer of stomach and lung responding to neoadjuvant chemotherapy].
  • Cancerous pleural effusion and gastric cancer was diagnosed, and the chemotherapy consisted of S-1 + DOC was started for Stage IV gastric cancer.
  • In 2009, lung cancer was found.
  • The chemotherapy was changed to CDDP + CPT-11.
  • This chemotherapy was effective for both lung and gastric cancers.
  • Operation was performed for both tumors in 2010, and the pathological diagnosis revealed that gastric cancer was pStage I, Cur A, and the lung cancer was pStage IA, R0.
  • Pathologic histology inspection of both tumors was judged to be effective for the chemotherapy prior to resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Neoadjuvant Therapy. Neoplasms, Multiple Primary / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Drug Combinations. Humans. Male. Oxonic Acid / administration & dosage. Taxoids / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224716.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


15. Vallières E: Role of adjuvant systemic therapy for stage I NSCLC. Thorac Surg Clin; 2007 May;17(2):279-85
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of adjuvant systemic therapy for stage I NSCLC.
  • Based on the limited data presented, in North America and in Europe. one cannot recommend the routine use of adjuvant systemic chemotherapy after the complete resection of stages IA and IB NSCLC.
  • The data from Japan are certainly intriguing and bring a potentially new adjuvant strategy for these patients: low-dose, long-term, well-tolerated adjuvant oral therapy.
  • In 2007, in Japan, adjuvant UFT is often recommended after the complete resection of stages IA and IB adenocarcinoma.
  • One also realizes that not every resected stage I tumor carries the same prognosis, a fact that most trials have not taken into consideration.
  • Despite the lack of trial results to support adjuvant chemotherapy in stage IA and IB diseases, however, outside of a clinical trial setting, it is probably reasonable to consider the possibility of adjuvant systemic chemotherapy in the individualized healthy younger patient whose resected tumor exhibited poor prognostic histologic findings, such as lymphovascular invasion, larger size, or even high fluorodeoxyglucose avidity on preoperative positron emission tomography scan.
  • Ideally, however, these patients should all be considered to participate in the next generation of trials exploring the strategy of adjuvant therapy in the management of completely resected stage I NSCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Neoplasm Staging. Pneumonectomy. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626406.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 18
  •  go-up   go-down


16. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, Usuda J, Kato H: The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg; 2007 Apr;13(2):73-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
  • Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with patients having a poor prognosis.
  • Approximately one third of NSCLC patients present with early-stage disease in which potentially curative resection and multi-modality therapy.
  • Although adjuvant chemotherapy is the standard practice for patients with stages I-III breast and colorectal cancer, the therapeutic efficacy of adjuvant chemotherapy, following complete surgical resection of early stage NSCLC, has not been fully established.
  • Several prospective randomized trials for patients with early stage NSCLC (stages I-IIIA) have confirmed a survival benefit with cisplatin-based adjuvant chemotherapy, as demonstrated in the 1995 meta-analysis performed by the NSCLC Collaborative Group.
  • Studies from Japan have reported that adjuvant therapy with uracil-tegaful (UFT) afforded an improvement of 4% in the 5-year survival rate and a relative risk reduction of 26% in mortality at 5 years among patients with T1-2N0 (stage I) disease.
  • In particular, the Japan Lung Cancer Research Group has demonstrated an improvement in the 5-year survival rate of 11%, favoring chemotherapy with UFT in the subset of patients with T2N0 (stage IB) disease.
  • The Lung Adjuvant Cisplatin Evaluation (LACE), which was based on a pooled analysis of five randomized trials, has demonstrated that cisplatin-based adjuvant chemotherapy improved survival in patients with completely resected NSCLC.
  • This benefit depended on stage, being greatest in patients with stage II or IIIA disease.
  • This analysis has suggested that platinum-based adjuvant chemotherapy may have no benefit for patients with stage IA and only a marginal benefit for patients with stage IB.
  • Thus, the information available at the current time supports the administration of adjuvant chemotherapy for patients who have undergone complete resection of stages IB-IIIA NSCLC.
  • Further research is needed to define the role of adjuvant platinum-based chemotherapy and its use, in conjunction with chest radiotherapy as the treatment for patients with resected stages IB and IIIA NSCLC.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / mortality
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Carboplatin / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Humans. Paclitaxel / therapeutic use. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505412.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 18
  •  go-up   go-down


17. Ono K, Nagashima A, Yokoyama E, Nose N, Yasumoto K: [Long-term survival after surgical resection of bone metastasis from lung cancer]. Kyobu Geka; 2010 Mar;63(3):216-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival after surgical resection of bone metastasis from lung cancer].
  • BACKGROUND: The prognosis of patients with bone metastasis from primary lung cancer is poor, and the effective treatment for bone metastasis had not been established.
  • CASE: A 56-years-old woman underwent right lower lobectomy and mediastinal lymph node dissection for lung cancer (well differentiated adenocarcinoma, pT1N0M0, stage IA) in another hospital in July 1995.
  • In May 2003, the patient suffered right lateral chest pain and the chest computed tomography (CT) showed an osteolytic mass of right 5th rib.
  • Percutaneous ultrasound-guided fine-needle aspiration cytology revealed adenocarcinoma and the tumor was diagnosed as bone metastasis from primary lung cancer.
  • A chest wall resection for bone metastasis of right 5th rib was carried out and she underwent adjuvant chemotherapy.
  • CONCLUSION: A resection of bone metastasis from lung cancer may offer the possibility of a long-term survival in selected patients.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Lung Neoplasms / pathology. Ribs

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20214351.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Parente B, Queiroga H, Teixeira E, Sotto-Mayor R, Barata F, Sousa A, Melo MJ, João F, Neveda R, Cunha J, Fernandes A, Manuel M, Cardoso T, Ferreira L, Nogueira F, Duarte J, Semedo E, Brito U, Pimentel F, Barros S, Costa F, Almodôvar T, Araújo A: [Epidemiological study of lung cancer in Portugal (2000/2002)]. Rev Port Pneumol; 2007 Mar-Apr;13(2):255-65
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiological study of lung cancer in Portugal (2000/2002)].
  • [Transliterated title] Estudo epidemiológico do cancro do pulmão em Portugal nos anos de 2000/2002.
  • Lung cancer is the most common form of cancer death in the world.
  • It is the 3rd most prevalent type of cancer in Portugal and the primary cause of cancer death.
  • 85% of lung cancer cases are attributable to smoking.
  • One study performed in Portugal for 3 years (2000/2002) by the Lung Oncology Work Committee of the Portuguese Society of Pulmonology in 22 Hospitals showed that of a total of 4396 patients with lung cancer, 81.8% were male and 18.2% were female, with a mean age of 64.49 +/- 11.28 years.
  • Histologically, 37.5% were adenocarcinoma, followed by squamous carcinoma in 30.5% of cases, and small cell lung cancer in 12.5%; neuroendocrine carcinoma presented in 1.4% of cases; non small cell lung cancer in 10.5%; mixed carcinoma in 0.7%; large cell carcinoma in 2.3%; and others/not specified in 4.6% of cases.
  • Staging (known in 4097 patients), showed 113 patients in stage IA (2.8%)and 250 patients in stage IB (6.1%); only 0.8% in stage IIA and 4.5% in stage IIB; 9.1% in stage IIIA and 29.9% in stage IIIB; 46.9% were already in stage IV by the time of diagnosis.
  • The first therapeutic option was known in 3855 patients.
  • Surgery was performed in 8.2% and 21.8% of cases were treated with combined therapies (surgery and chemotherapy or radiotherapy, or combination of chemotherapy and radiotherapy); chemotherapy alone was first choice in 43.7% of patients and in 20.3% only best support therapy was chosen.
  • [MeSH-major] Lung Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571453.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


19. Kanematsu T, Hanibuchi M, Tomimoto H, Sakiyakma S, Kenzaki K, Kondo K, Bando H, Haku T, Yoneda K, Hirose T, Toyoda Y, Goto H, Sakaguchi S, Kinoshita K, Azuma M, Kakiuchi S, Kishi J, Azuma M, Tada H, Sumitomo M, Nishioka Y, Yano S, Sone S: Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan. J Med Invest; 2010 Aug;57(3-4):326-33
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan.
  • Lung cancer is the leading cause of malignancy-related death worldwide.
  • In the present study, we reviewed the epidemiologic and clinical features of lung cancer in Tokushima Prefecture, Japan.
  • Between January 1999 and December 2009, 2,183 patients with lung cancer were enrolled in this study.
  • One thousand nine hundred five (87%) patients were non-small cell lung cancer and the predominant histological type was adenocarcinoma (51%).
  • Four hundred seventy-one (22%), 213 (10%), 24 (1%), 116 (5%), 238 (11%), 370 (17%) and 678 (31%) patients had stage IA, IB, IIA, IIB, IIIA, IIIB and IV lung cancer, respectively.
  • In Tokushima University Hospital, 516 (29%), 191 (11%), 58 (3%), 755 (43%) and 216 (12%) patients were initially treated with chemotherapy, chemo-radiotherapy, thoracic radiotherapy, operation and best supportive care, respectively.
  • The median time to progression (TTP) and the median survival time (MST) of patients treated with chemotherapy and chemo-radiotherapy were 3.5 months, 13.0 months and 7.0 months, 18.0 months, respectively.
  • The median TTP and the MST of 33 elderly patients treated with chemotherapy were 3.3 months and 18.0 months, respectively, which were comparable with those of total population.
  • These results indicated the benefit of chemotherapy in elderly patients with advanced lung cancer by proper selection.
  • [MeSH-major] Lung Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Small Cell / epidemiology. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / therapy. Female. Humans. Japan / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Risk Factors. Smoking / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847534.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Wei WD, Wen ZS, Su XD, Lin P, Rong TH, Chen LK: [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection]. Ai Zheng; 2007 Nov;26(11):1231-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection].
  • BACKGROUND & OBJECTIVE: Multi-disciplinary management for non-small cell lung cancer (NSCLC) has been applied for more than ten years.
  • RESULTS: The 5-year survival rate of the 899 patients was 43.5% and the median survival time was 48 months.
  • The 5-year survival rates were 81.0% for the patients at stage IA, 60.3% for stage IB, 56.9% for stage IIA, 45.7% for stage IIB, 23.5% for stage IIIA, 20.8% for stage IIIB, and 13.0% for stage IV.
  • Univariate analysis showed that T stage, N stage, M stage, histological type, differentiation, chemotherapy for adenocarcinoma (ADC) at stages II and IV, and mediastinal radiotherapy for ADC at stage N2 were prognostic factors.
  • Multivariate analyses showed that histological type, T stage, N stage, M stage and mediastinal radiotherapy for ADC at stage N2 were independent prognostic factors.
  • CONCLUSION: Besides T stage, N stage, and M stage, histological type and mediastinal radiotherapy for ADC at stage N2 are also independent prognostic factors of NSCLC after complete resection.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods


21. Escuín JS: [Lung cancer in Spain. Current epidemiology, survival, and treatment]. Arch Bronconeumol; 2009 Jul;45(7):341-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer in Spain. Current epidemiology, survival, and treatment].
  • [Transliterated title] El cáncer de pulmón en España. Epidemiología, supervivencia y tratamiento actuales.
  • In 2005, 19 115 people died of lung cancer in Spain.
  • While the proportion of adenocarcinomas relative to other histological types has increased worldwide, squamous cell carcinoma still predominates in Spain (ranging from 24%-50.5%).
  • Between 25% and 50% of patients receive only palliative medication.
  • Absolute overall survival in patients with lung cancer is under 10% in many countries.
  • The 5-year survival rate among patients treated surgically has increased slightly, with stage IA rates ranging from 58.3% to 68.5% and stage IIIA from 28.3% to 35.8%.
  • [MeSH-major] Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / mortality. Adenocarcinoma / therapy. Age Distribution. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Comorbidity. Drug Utilization. Europe / epidemiology. Female. Humans. Incidence. Male. Mass Screening. Mortality / trends. Palliative Care. Pneumonectomy / mortality. Pneumonectomy / utilization. Sex Distribution. Spain / epidemiology. Survival Rate. United States / epidemiology. Waiting Lists

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324488.001).
  • [ISSN] 1579-2129
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Younes RN, Deutsch F, Badra C, Gross J, Haddad F, Deheinzelin D: Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution. Rev Hosp Clin Fac Med Sao Paulo; 2004 Jun;59(3):119-27
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution.
  • OBJECTIVE: To analyze surgical and pathological parameters and outcome and prognostic factors of patients with nonsmall cell lung cancer (NSCLC) who were admitted to a single institution, as well as to correlate these findings to the current staging system.
  • Following staging, a multidisciplinary team decision on adequate management was established.
  • Variables included in this analysis were age, gender, histology, Karnofsky index, weight loss, clinical stage, surgical stage, chemotherapy, radiotherapy, and survival rates.
  • The distribution of histologic type was squamous cell carcinoma 51.8%, adenocarcinoma 43.1%, and undifferentiated large cell carcinoma 5.1%.
  • Clinical staging was IA 3.8%, IB 9.2%, IIA 1.4%, IIB 8.1%, IIIA 20.9%, IIIB 22.4%, IV 30.9%.
  • Surgical stage distribution was IA 25.3%, IB 1.4%, IIB 17.1%, IIIA 16.1%, IIIB 20.3%, IV 11.5%.
  • Chemotherapy and radiotherapy were considered therapeutic options in 43% and 72%, respectively.
  • The overall 5-year survival rate of nonsmall cell lung cancer patients in our study was 28%.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15286831.001).
  • [ISSN] 0041-8781
  • [Journal-full-title] Revista do Hospital das Clínicas
  • [ISO-abbreviation] Rev Hosp Clin Fac Med Sao Paulo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


23. Vlastos F, Lacomme S, Wild P, Poulain S, Siat J, Grosdidier G, du Manoir S, Monga B, Hillas G, Varsovie R, Claudot F, Marie B, Vignaud JM, Szymanski N: Do evolving practices improve survival in operated lung cancer patients? A biobank may answer. J Thorac Oncol; 2009 Apr;4(4):505-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do evolving practices improve survival in operated lung cancer patients? A biobank may answer.
  • INTRODUCTION: Biobanks may play a pivotal role in lung cancer patients' management, research, and health policy.
  • The Nancy "Centre of Biologic Resources" analyzed the evolving profiles of operated lung cancer patients and their management over 20 years.
  • RESULTS: After 1997, lung cancer was diagnosed at an earlier stage.
  • For Squamous Cell Lung Cancer (SQCLC), stages IA increased from 5.4 to 19.5% and for Adenocarcinoma (ADC), stage IA increased from 9.9 to 24.7%.
  • More women with stage I ADC were operated upon after 1997 (p = 0.01).
  • More patients with Large Cell Lung Cancer were diagnosed recently.
  • Recent patients received more adjuvant or neo-adjuvant chemotherapy (p < 0.001) and less radiotherapy (stage I SQCLC: p = 0.019, stage I ADC: p < 0.001).
  • Among SQCLC long survivors, those at stage I-II, below 50 years, were more numerous.
  • A longer survival was associated with early stage in ADC patients.
  • Stage was the single constant factor for overall outcome.
  • CONCLUSION: Overall and stage-adjusted survival of operated lung cancer patients has been improved in the last decade due mainly to earlier diagnosis.
  • The generalized use of computed tomography scan, chemotherapy, and a collegial management improved patients' survival.
  • [MeSH-major] Lung Neoplasms / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240651.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Sawada S, Komori E, Nogami N, Segawa Y, Shinkai T, Yamashita M: Evaluation of lesions corresponding to ground-glass opacities that were resected after computed tomography follow-up examination. Lung Cancer; 2009 Aug;65(2):176-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of lesions corresponding to ground-glass opacities that were resected after computed tomography follow-up examination.
  • BAC is considered to be a relatively less aggressive tumor, and immediate resection at the time of detection might not be necessary.
  • However, the possible treatment delay caused by the scheduling of a CT follow-up examination is an issue that must be clarified.
  • This study attempted to clarify whether CT follow-up causes treatment delay.
  • METHODS: A total of 113 lung cancer patients with pure or mixed GGO findings who underwent a resection after a CT follow-up examination between 1999 and 2005 were retrospectively examined.
  • The CT findings at the initial detection, the changes in the CT findings during the CT follow-up period, the histology, the pathological stage and the outcomes after resection were reviewed and evaluated.
  • RESULTS: The CT finding at the time of the initial detection showed pure GGO in 63 patients and mixed GGO in 50 patients.
  • Histology revealed that adenocarcinoma was found in all 113 patients; squamous cell carcinoma was not found in any of the patients.
  • One-hundred twelve patients were diagnosed as having Stage IA, and a singe patient with visceral pleura invasion was diagnosed as having Stage IB.
  • CONCLUSIONS: No treatment delays or negative influences on patient outcome resulted from the CT follow-up period.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / radiography. Lung Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135757.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


25. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1272-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
  • PURPOSE: To evaluate the outcome and patterns of failure in women with uterine clear-cell carcinoma and discuss implications for adjuvant radiation therapy (RT).
  • Thirty-eight women (5.5%) had clear-cell tumors (18 clear-cell only, 8 clear-cell + adenocarcinoma, and 12 clear-cell + other unfavorable histologies [10 papillary serous, 1 uterine sarcoma, 1 both]).
  • FIGO stages were as follows: 3 IA, 4 IB, 5 IC, 4 IIA, 6 IIB, 8 IIIA, 2 IIIB, 3 IIIC, and 6 IV.
  • Adjuvant therapies included the following: 5 none, 22 RT (13 pelvic RT, 2 vaginal brachytherapy, 7 both), 11 chemotherapy (8 alone, 3 after pelvic RT), and 3 hormones.
  • No correlation was seen between relapse and stage, myometrial invasion, cytology, cervical extension, or involvement of extrauterine sites.
  • Patients with clear +/- adenocarcinoma histology had a similar 5-year disease-free survival (38.8% vs. 38.7%, p = 0.95) compared with those with clear-cell + other unfavorable histologies.
  • Corresponding pelvic failure rates in the Stage IA-IIB patients with and without RT were 0/16 (0%) and 5/6 (83%) (p < 0.0001).
  • Only 1 (2%) patient developed an isolated abdominal failure (This patient had a mixed clear-cell/papillary serous tumor).
  • Of the 26 women with clear-cell +/- adenocarcinoma histology, only 1 (3.8%) relapsed in the abdomen.
  • Future protocols should focus instead on combinations of locoregional RT and chemotherapy to reduce the risk of local and systemic recurrence.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Radiotherapy, Adjuvant
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Pelvic Neoplasms / secondary. Prognosis. Sarcoma / pathology. Treatment Failure. Treatment Outcome. Uterine Neoplasms / pathology. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654437.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 30
  •  go-up   go-down


26. Tropé C, Kristensen GB, Abeler VM: Clear-cell and papillary serous cancer: treatment options. Best Pract Res Clin Obstet Gynaecol; 2001 Jun;15(3):433-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell and papillary serous cancer: treatment options.
  • The histological diagnosis can be made on the dilation and curettage specimens in both types in a very high percentage of the cases.
  • This is important in the planning of treatment.
  • Surgico-pathological stage, age, and vessel invasion are independent prognostic factors for both groups.
  • Stage Ia patients treated with complete surgical staging alone have a low risk of relapse and need not be offered adjuvant systemic therapy or pelvic radiation.
  • The treatment of patients with CCC and UPSC stage Ib, Ic, II and III should include radical debulking surgery and some form of adjuvant therapy, but it is not clear which type is most effective.
  • Adjuvant pelvic radiotherapy plus intracavitary radiotherapy is usually given in early-stage disease and pelvic radio therapy/or whole abdomen irradiation plus adjuvant systemic chemotherapy (PAC) in advanced disease.
  • [MeSH-major] Adenocarcinoma, Clear Cell / therapy. Cystadenocarcinoma, Papillary / therapy. Endometrial Neoplasms / therapy
  • [MeSH-minor] Age Factors. Aneuploidy. Combined Modality Therapy. Dilatation and Curettage. Female. Genes, p53. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Neoplasm Invasiveness / genetics. Neoplasm Staging. Prognosis. Transcriptional Activation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Harcourt Publishers Ltd.
  • (PMID = 11476564.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


27. Kim S, Wu HG, Lee HP, Kang SB, Song YS, Park NH, Ha SW: Patterns of failure after postoperative radiation therapy for endometrial carcinoma. Cancer Res Treat; 2006;38(3):133-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after postoperative radiation therapy for endometrial carcinoma.
  • PURPOSE: We tried to investigate the outcome and patterns of failure of endometrial cancer patients who were treated with surgery and postoperative radiation therapy (RT).
  • All the patients were staged according to 1988 FIGO (International Federation of Gynecology and Obstetrics) staging system; 2 were stage IA, 23 were stage IB, 20 were stage IC, 4 were stage IIA, 5 were stage IIB, 9 were stage IIIA, 2 were stage IIIB and 18 were stage IIIC.
  • The histologic diagnoses were adenocarcinoma in seventy-four patients (89%).
  • RESULTS: Overall, 11 patients (13%) experienced disease relapse: 4 with initial stage I or II disease and 7 with initial stage III disease.
  • Among the 54 stage I or II patients, 1 (2%) relapsed in the pelvis only, 2 (4%) relapsed in the vagina and distant organs, and 1 (2%) relapsed in the paraaortic lymph nodes (PANs).
  • Among the 29 stage III patients, 1 (3%) relapsed in the vagina.
  • The most common sites of failure for the stage III patients were the peritoneum (3 patients, 10%), PANs (2 patients, 7%), and lung (2 patients, 7%).
  • The five-year DFS rate was 93%, 100% and 74% for the stage I, II and III patients, respectively.
  • Three patients experienced severe radiation-related late complications: RTOG (Radiation Therapy Oncology Group) grade 3 radiation cystitis was seen in one patient, and grade 3 bowel obstruction was seen in two patients.
  • The major patterns of failure for stage III patients were peritoneal seeding and distant metastasis.
  • Selective use of whole abdominal radiotherapy or adjuvant chemotherapy may improve the therapeutic outcome of these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):233-8 [11161865.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):79-85 [11006036.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):101-4 [9747826.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):138-44 [7729725.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Nov;4(6):373-6 [1463690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):905-11 [1555983.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):68-70 [2703169.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):276-8 [3280811.001]
  • [Cites] Radiobiol Radiother (Berl). 1987;28(4):519-28 [3685293.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] Cancer Treat Rep. 1979 Jan;63(1):21-7 [369691.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):236-42 [12713986.001]
  • [Cites] Gynecol Oncol. 2002 Dec;87(3):274-80 [12468325.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):437-42 [11855884.001]
  • (PMID = 19771273.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2741680
  • [Keywords] NOTNLM ; Endometrial neoplasms / Patterns of failure / Postoperative radiation therapy
  •  go-up   go-down


28. Abdel Rahman AR: Bronchoplasty for primary broncho-pulmonary tumors. J Egypt Natl Canc Inst; 2010 Mar;22(1):73-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between 2000 and 2009, 36 patients with primary lung tumors required bronchoplasty were retrospectively analyzed.
  • Preoperative assessment included computed tomography (CT) of the chest, bronchoscopy, and spirometry.
  • Pre operative diagnosis was acheived by bronchoscopy for all patients, mediastinoscopy was done for patients with primary lung cancer.
  • Neo adjuvant chemotherapy was given for 6 patients with non small cell lung cancer (NSCLC).
  • Post operative pathology revealed: 27 patients with typical carcinoid, 2 with atypical carcinoid, 4 with squamous cell carcinoma, 2 with adenocarcinoma and one with hamartoma.
  • Pathological TNM staging revealed: 17 patients with stage IA, 11 with IB, 5 with IIA and 2 with stage IIIA.
  • The patient with hamartoma developed local recurrence 5 years later and re-excision was done.
  • One patient with lung cancer developed bone metastases and was alive with disease, while the remaining 30 patients were alive and disease free.
  • KEY WORDS: Bronchoplasty - Primary - Lung - Tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21503009.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down






Advertisement